INTRODUCTION
Invasive pulmonary aspergillosis (IA) is incre asingly reported in patients with hematologi cal malignancies [1] . Hemoptysis is a frequent complication, occurring in 5083% of patients with IA [1] . Massive hemoptysis (MH), defined as a blood loss of more than 300600 ml cou ghed up within 24 hours; it occurs in 510% of patients and, as a medical emergency requires immediate treatment [2] . Standard treatment measures include: supplemental oxygen, posi tioning the patient with the bleeding site down, bronchoscopical suctioning, antifungal therapy, transfusion support and emergency surgical resection in combination with antifungal tre atment [2, 3] .
Hemoptysis, usually moderate, was regis tered in a considerable number of our patients with IA. Antifungal therapy, alone or accompa nied with other standard measures, stopped the bleeding in the majority of patients. We report two patients with MH who were treated in a nonstandard way.
CASE REPORT 1
A 61yearold male with acute myeloid leuke mia (AML) M2, normal karyotype, interme diate risk group, Eastern cooperative oncology group performance status 2, had been treated with the "MRC 10" protocol, induction che motherapy "ADE 3+5+10" (cytosine arabi noside, daunorubicyn and etoposide) with subsequent achievement of complete remis sion. After a consolidation cycle "ADE 3+5+8" he experienced febrile neutropenia lasting for 15 days. All the time he had been receiving Fluconasole as antifungal prophylaxis. On the 32nd day the patient was febrile with a com plete blood count (CBC): hemoglobin (Hb) 98 g/L, white blood count (WBC) 2.0×10 9 /L with 43% neutrophils, platelet count 80×10 9 /L. A chest Xray showed focal bronchopneumonia of the left lung (at the junction of the VII and IV ribs). Neither highresolution computer tomo graphy (CT) nor the galactomannan tests were available. The culture from the central venous catheter was positive for Aspergillus niger and the blood culture for Staphylococcus aureus. Risk factors for invasive fungal infection (IFI) were prolonged neutropenia (lasting 15 days), a central vein catheter (CVC), advanced age, AML and persistent fever for 72 hrs refractory to broadspectrum antibiotic treatment. The antibiotic therapy was modified (Vancomycin) and antimycotic therapy (Amphotherycin B 1 mg/kg) was initiated. Two days later MH deve loped. There was no evidence of a hemostatic defect as the platelet count was 100×10 9 /L, fibrinogen 3.54 g/L, prothrombin time (PT) SUMMARy Introduction Invasive pulmonary aspergillosis (IA) is the most frequent invasive fungal infection in patients with hematological malignancies. Massive hemoptysis (MH) with blood loss more than 300 600 ml in 24 hours is a rare (510% of IA patients) but frequently fatal complication. Standard treatment of MH, such as oxygenation, a semisitting position with the bleeding site down, bronchoscopical suctioning, antifungal therapy, transfusion support and surgical resection might be either ineffective or not feasible in some cases. Outline of Cases We report two patients with life threatening, noncontrolled, massive hemoptysis who were successfully managed by nonstandard measures. A 61yearold male with acute myeloid leukemia developed pulmonary IA and massive hemoptysis after consolidation cure by chemotherapy. The bleeding site was localized in the VI lung segment by bronchoscopy. Local application of fibrinogenthrombin concentrate (fibrin glue) stopped the bleeding. A 22yearold female patient with the diagnosis of severe aplastic anemia developed IA and massive hemoptysis early after application of immunosuppressive therapy (antilymphocyte globulin, cyclosporine and corticosteroids). Conventional transfusion therapy, desmopresine and antifibrinolytics were ineffective. This urgent condition was successfully treated with human activated recombinant factor VII (rFVIIa, NovoSeven®). Conclusion Our experience together with data from the available literature suggests a potential benefit of fibrinogenthrombin concentrate and rFVIIa in the treatment of refractory critical bleeding in hemato oncological patients. keywords: invasive pulmonary aspergillosis; massive hemoptysis; rFVIIa; fibrinogenthrombin concentrate 9 /L, but with no significant effect on MH intensity. Tranexamic acid (Ciclokapron®) and desmopre sine (Emosint®) were also ineffective. Bronchoscopy with infusion of fibrinogenthrombin was unmanageable due to the diffuse pattern of bleeding. Faced with this life thre atening situation human activated recombinant factor VII (rFVIIa, NovoSeven®, NovoNordisk) at a bolus dose of 90 µg/kg (total dose 4.8 mg) was administered, followed by complete cessation of hemoptysis. Despite this hemosta tic effect hypoxemia progressively worsened (pO2 4662 kPa) and the patient was placed on mechanical ventilation. Unfortunately, multiple organ failure developed followed by death 30 hours after the onset of bleeding and 6 hours after Novo Seven initiation.
DISCUSSION
MH is a well described and frequent fatal complication of IA [1, 2, 4] . Standard treatment might be ineffective and surgical resection may be unfeasible due to difficulty in identifying the bleeding site and time delay to surgery [2, 3, 4] .
IA is the second most common fungal infection in acute leukemia, occurring in 5-25% of patients [1, 4] . Minor hemoptysis has been reported in up to 58% of patients with IA and AML. On the other hand, massive fatal hemoptysis is rare and usually happens during bone marrow recov ery [2, 3, 4] . In our first AML patient, localized bleeding in the sixth lung segment was successfully managed by the local application of fibrinogenthrombin concentrate via bronchoscopy. According to our experience and data in the literature, local infusion of fibrinogenthrombin is established as a simple and effective therapy for localized hemoptysis [5, 6] .
rFVIIa is a hemostatic agent originally developed for the treatment of hemorrhage hemophiliacs with inhibitors [7, 8] . The supraphysiological level of FVIIa resulting from an injection of 90 µg/kg (approximately 25 times normal), combined with abundant tissue factor exposed to suben dothelial cells of the damaged vessels, was necessary to gen erate sufficient thrombin for a stable clot formation [7, 8] .
In the last few years rFVIIa has been employed with success in many "off label" bleeding conditions unresponsive to standard therapy [9, 10, 11] . A systematic literature review from 2007 recorded 162 hematooncological patients with bleeding (49 nontransplanted/ 113 transplanted), who were treated with rFVIIa. Cessation or significant reduc tion in either blood loss or need for blood transfusion was obtained in 93.9% of the nontransplanted and in 61.1% of the transplanted patients [10] .
Local intrapulmonary administration of rFVII is a new, attractive treatment option for critical pulmonary bleeding. Symptomatic therapy of diffuse alveolar hemorrhage with intrapulmonary administration of rFVIIa in six patients, in a lower dose (50 µg/kg vs. 90 µg/kg), was found to have a hemostatic effect in all patients without adverse events [12] . In our patient with severe aplastic anemia and MH, the context of conventional therapy for IA was ineffective. This urgent condition was successfully treated with rFVIIa.
Our experience showed that standard therapy measures for MH in IA could be ineffective or not feasible and sug gests benefit from a nonstandard therapy approach, like rFVIIa therapy or local application of fibrinogenthrombin concentrate via bronchoscopy. However, most currently available literature data concerning nonstandard therapy are derived from uncontrolled studies including single cases or small series of patients [912] . Thus, future trials with a larger number of patients are needed to establish indications for both local fibrinogenthrombin concentrate and rFVIIa therapy, as well as to assess the most appropriate mode of application, timing, optimal dosage of rFVIIa and its efficacy and safety in this setting.
КРАТАК САДРжАЈ
Увод Ин ва зив на аспер ги ло за (ИА) плу ћа је нај че шћа ин ва зив на гљи вич на ин фек ци ја код бо ле сни ка с хе ма то ло шким ма лиг ни те ти ма. Ма сив на хе моп ти зи ја (МХ), са гу бит ком кр ви ве ћим од 300600 ml за 24 са та, је сте рет ка (510% бо ле сни ка са ИА), али че сто смр то но сна ком пли ка ци ја. Стан дард ни при ступ ле че њу МХ, ко ји под ра зу ме ва по ста вља ње бо ле сни ка у по лу се де ћи по ло жај, ок си ге на ци ју, брон хо скоп ску сук ци ју, ан ти гљи вич ну те ра пи ју, тран сфу зи о ну пот по ру и хи рур шку ре сек ци ју, че сто је не е фи ка сан или не до сту пан за хе ма то ло шке бо ле сни ке с по ре ме ћа ји ма хе мо ста зе. При ка зи бо ле сни ка При ка зу је мо два бо ле сни ка с ма сив ном, по жи вот опа сном и не кон тро ли са ном хе моп ти зи јом ко ји су успе шно ле че ни не стан дард ним при сту пом. Код бо ле сни ка ста рог 61 го ди ну са ди јаг но зом акут не ми је ло ид не ле у ке ми је ИА плу ћа пра ће на МХ се раз ви ла по при ме ни кон со ли да ци о не ку ре хе ми о те ра пи је. Ме сто кр ва ре ња је брон хо скоп ски ло ка ли зо ва но у ше стом плућ ном сег мен ту. То ком брон хо ско пи је ло кал но је при ме њен кон цен трат фи бри но ге на и тром би на (фибрински лепак), чи ме је кр ва ре ње за у ста вље но. Код бо ле сни це уз ра ста од 22 го ди не са ди јаг но зом апла стич не ане ми је те шког сте пе на ИА плу ћа и МХ су се раз ви ле не по сред но на кон при ме не иму но су пре сив не те ра пи је (ан ти лим фо цит ни гло бу лин, ци кло спо рин и кор ти ко сте ро и ди). Кон вен ци о нал на тран сфу зи о на те ра пи ја, де змо пре син и ан ти фи бри но ли ти ци ни су зна чај но сма њи ли кр ва ре ње. Ово хит но ста ње је успе шно збри ну то при ме ном ак ти ви ра ног ре ком би нант ног фак то ра VII (rF VI Ia, No vo Se ven®). За кљу чак На ше ис ку ство уз по дат ке из ли те ра ту ре ука зу је на по тен ци јал но зна чај ну уло гу кон цен тра та фи бри но ге на и тром би на и rF VI Ia у ле че њу ре фрак тер них, жи вот но угро жа ва ју ћих кр ва ре ња код хе ма то он ко ло шких бо ле сни ка са ИА плу ћа и МХ.
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